(CLIP) Atty Aaron Siri REVEALS Shocking Truth Behind Vaccine Trials - w' Russel Brand

WATCH THE FULL INTERVIEW: https://rumble.com/v5zbkze-aaron-siri-reveals-shocking-truth-behind-vaccine-trials-w-russel-brand-full.html?mref=1bxo9j&mc=69gy3

[SEE ALSO:
- Aaron Siri - Why Are Vaccine Manufacturers the Most Protected Companies in America? (2 part interview)
https://rumble.com/v3woj01-aaron-siri-why-are-vaccine-manufacturers-the-most-protected-companies-in-am.html?mref=1bxo9j&mc=69gy3 ]

Aaron Siri: "And this is the FDA's own website, their own information in which it's made explicitly clear that the follow-up for some of these vaccines is just five days. So if they go and see someone, if they check in on someone five days later, and they're not coughing up blood, their project is declared a success."

"Well, the way to think, yes, that's close, but the way to think about it is this. When you wanna license a product, okay, you have to do a clinical trial. And why are clinical trials so critically important? They're critically important because it's the only time that's considered ethical with a vaccine to give one group the vaccine and one group nothing, a placebo, and then compare them."

"Because once it's licensed, they say, oh, it's unethical to withhold the vaccine now from any child. So the clinical trial is critically important to show the safety because after licensure, all you can really do are what's known as retrospective epidemiological study, okay? And they will tell you, the epidemiologists and the scientific community will tell you, you can't prove causation with those studies. You can just show correlation, not causation. How do you prove causation?"

"If somebody comes to our firm and says, hey, I believe this product caused this injury and I wanna show causal connection, I need typically clinical trial data. So that's why the clinical trials are so critical. And those safety review periods that we just looked at and the controls, okay. Those are from the clinical trials."

"When you want to license a product, the company that wants to license it conducts the clinical trial, not the FDA, not any European or UK health authorities. The company conducts the trial. It then submits that data to the regulatory authority. They decide then whether to license it. What are you submitting?"

"Clinical trial. How do you evaluate whether a clinical trial is good? Number one, how long do you review safety? If you didn't look at it long enough, you got a baby. You only followed in the clinical trial, say for five days, most immune issues might not come up for a few years of age, like asthma, developmental issues for numerous years of age. Even like autoimmunity, think about it like this."

"If I give you a vaccine and I say, you're gonna get immunity to a certain antigen in the product, that will often, they tell you, take many weeks or months. So if you're gonna have self-attacking antibodies, that will at least take weeks or months, not five days, it's not gonna show up in five days. So how long, that's criteria one. Second, well, what are you comparing it against?"

"Because even if I review safety for a long time, but I don't have a placebo control group or another control group where I really understand the safety profile, how do I know it's safe? What am I comparing it against? The background rate, it's really hard to do that. And then finally, the third factor is you gotta have enough people in the trial, okay? Hope I'm not boring your audience with this. The third criteria is you gotta have enough people to what epidemiologists would call it has to be well-powered."

"If you don't have enough people, then you're not going to detect signals. If you only have a few thousand kids, well, then you're only going to detect conditions that happen, you know, one in a thousand, one in a few hundred, meaning you're not going to catch rare things. And when you're injecting this into millions of kids and requires giving often, let's say eight thousand nine, twenty, thirty thousand vaccines prevent one case of disease."

"Well, you better be safer than that number is called the number two treat. So if the number two treat is twenty thousand injections to stop one adverse event from the underlying disease, well, you better make sure the product's safer than one in 20,000 adverse events. So you gotta be properly careful."

"Okay, with that said, what we're looking to look at is what was the clinical trial, what were the features of the clinical trial that the company relied upon, excuse me, that the FDA relied upon to license this product? What did they accept? And in that chart, I mean, I will, I'll share my screen again. So we're back to this chart again, right? And that's what it means by safe follow-up. So let's take a look at the first one on the list, hepatitis B vaccine."

"That's the very first licensed childhood vaccine. And if we go to Google, and we go to FDA licensed vaccines, so here we are, we're now gonna click on the first link, vaccines licensed for use in the United States. On this webpage is every single vaccine's license for use in the United States. These are not very dissimilar for the ones in Europe as well."

"I understand sometimes they have different brand names and so forth. If we scroll down, we will find there are four hepatitis B vaccines licensed in the United States. Only two of these are licensed for babies, the other two are only for adults. The first one, the comma vaccine HB is the one that was licensed."

"It was licensed actually in 1986 when we pull up the package insert, and I don't know what it's like in the UK or in other parts of the world, but in the United States, when you get a drug, there's usually a piece of paper in the box. Yes. When you open it, it becomes very big, huge, right? Yeah, really easy to read. They make it entertaining. There's cartoon characters. It's a very appealing document. Definitely getting, they must be very different than where you are than the ones we have, but those definitely sound more exciting."

"Under federal regulations, section 6.1, I'll scroll down, require that the manufacturer summarize the clinical trial relied upon to license that product, vis-a-vis safety, perfect. So there's a simple way to look at the clinical trial. I'm about to inject this into my baby, okay? Now, before I go and buy a car, I kick the tires, ask a few questions before I... You know, I do my homework right before you buy any product."

"You do, but even you go to Amazon, you're going to buy like a camera. You're going to do some research before you inject something into your baby. If you want to start by looking at what was the safety, how did it determine say, this is probably the place to start. I would say, and we'll scroll down to set 6.1 and right here, we will see, this is all of the text of section 6.1."

"These were the reactions reported in the clinical trial. Section 6.2 is the post marketing safety. So this sentence summarizes the clinical trial allowed upon to license this product for children. 434 doses were administered to 147 infants and children up to 10 years of age who were monitored for five days after each dose."

"So that product being issued after it's only been given to 147 kids. and they've only done less than 500 doses and their follow-up period is five days. That's not even really a clinical trial. I reckon I could get together a trial of that standard from previous partners. I think you're being kind. That's incredible. I mean, because if I did now, now I just want to remind everybody, we're on the FDA website. Last I checked, not an anti-vax organization, I think. And this is a FDA approved document."

"This is Merck summation of it. And I will tell you the first time I saw this, I actually said it can't be, it cannot be that a product that you're gonna inject into millions of babies is licensed based on five days of safety monitoring after injection, that there's gotta be more. So we actually submitted something called a Freedom of Information Act request, a FOIA request."

"That's a law in the United States that allows us to get documents from the federal government here. And I asked, we asked on behalf of our client, the Informed Consent Action Network, ICAN, we asked for all of the clinical trial reports that were submitted to license thinking, there's got to be more in there. And we got copies of all of them."

"And they're on the ICAN website. Anybody can go see them. And it's five days. And in fact, we then even petition the FDA and the formal docking system that Merck and Pfizer and companies use to license or to modify licensures to say, Hey, you know, Congress said you should only license products that are shown to be safe. Now we can debate whether the safety of your period, how many kids need to be. and what the control should be, right?"

"We could debate those things maybe in the margins. Should it be 100,000 kids, 50,000 kids? Should it be five years, three years? But five days with 147 kids? And what was the control? Right, there's none listed. She's useless. It's utterly and completely useless to determine safety. So the company, they did this into, Merck got this on the market with the absolute minimum safety data that they could obtain."

"And if somebody out there will say to you, well, Maybe they already knew it was safe because, and these are the arguments I often hear in return. Well, they knew it was safe because there was probably other Hep B, you know, the vaccines. This is the very first recombinant DNA technology vaccine in the universe."

"Just like the very first mRNA vaccine was COVID, the very first recombinant DNA technology vaccine ever was this hepatitis B vaccine in the United States. And there was, at that point, there had been a prior Hep B vaccine made actually with literal human blood. Nobody wanted to take it. So that went away. So there's no precedent, safety profile."

"The other argument I often hear is, yeah, well, but they probably really tested it in adults well. Well, let's just scroll down just right to this sentence and we could see how they tested it in adults. 1,200 people, so better a little bit, but still completely underpowered. And again, only five being completely moderate. And again, you can see the clinical trial reports."

"So, you know, I've deposed the x-knowledges, immunologists, pediatricians, and you know, I've asked about this a million times. I've waited for, there is no response to this. There's no good response to this. If you're looking, if you think there's something else, send it to me. I'd love to see it, because that's what there is in terms of what was lied upon to license this product."